Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2019 | 803 | 3.280 |
Why?
|
| Autophagy | 13 | 2018 | 56 | 2.440 |
Why?
|
| Heat-Shock Proteins | 6 | 2019 | 44 | 2.220 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2018 | 113 | 2.090 |
Why?
|
| Estrogen Receptor Modulators | 6 | 2017 | 30 | 1.760 |
Why?
|
| Unfolded Protein Response | 8 | 2019 | 15 | 1.620 |
Why?
|
| Diet, Mediterranean | 2 | 2019 | 32 | 1.160 |
Why?
|
| Drug Discovery | 2 | 2015 | 38 | 0.910 |
Why?
|
| Apoptosis | 9 | 2018 | 400 | 0.840 |
Why?
|
| Mammary Glands, Human | 2 | 2019 | 14 | 0.720 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 627 | 0.710 |
Why?
|
| Tamoxifen | 3 | 2017 | 66 | 0.660 |
Why?
|
| Neoplasms | 2 | 2019 | 791 | 0.650 |
Why?
|
| Animals | 22 | 2021 | 8544 | 0.630 |
Why?
|
| Bacteria | 1 | 2019 | 56 | 0.590 |
Why?
|
| Estrogen Antagonists | 3 | 2014 | 20 | 0.550 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 54 | 0.520 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 174 | 0.510 |
Why?
|
| Female | 23 | 2021 | 21491 | 0.500 |
Why?
|
| Estradiol | 2 | 2014 | 156 | 0.500 |
Why?
|
| Mice | 11 | 2019 | 2691 | 0.480 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 113 | 0.480 |
Why?
|
| Signal Transduction | 7 | 2019 | 765 | 0.470 |
Why?
|
| Humans | 26 | 2021 | 34475 | 0.460 |
Why?
|
| Breast | 1 | 2015 | 68 | 0.440 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 117 | 0.440 |
Why?
|
| Hydroxychloroquine | 1 | 2014 | 11 | 0.430 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2017 | 27 | 0.370 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 37 | 0.370 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 7 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 31 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 180 | 0.290 |
Why?
|
| Angiotensin I | 1 | 2010 | 239 | 0.290 |
Why?
|
| Peptide Fragments | 2 | 2011 | 430 | 0.280 |
Why?
|
| Mice, Nude | 3 | 2014 | 290 | 0.280 |
Why?
|
| Blotting, Western | 3 | 2014 | 328 | 0.280 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 378 | 0.260 |
Why?
|
| Mammary Glands, Animal | 2 | 2019 | 69 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 772 | 0.260 |
Why?
|
| Cell Proliferation | 4 | 2018 | 628 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 46 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 118 | 0.210 |
Why?
|
| Diet | 3 | 2021 | 418 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 56 | 0.190 |
Why?
|
| Bacteroides | 1 | 2021 | 8 | 0.170 |
Why?
|
| Prevotella | 1 | 2021 | 8 | 0.170 |
Why?
|
| Lactobacillus | 1 | 2021 | 13 | 0.170 |
Why?
|
| Feces | 1 | 2021 | 43 | 0.170 |
Why?
|
| Primates | 1 | 2021 | 130 | 0.160 |
Why?
|
| Endoribonucleases | 1 | 2019 | 5 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 6 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 201 | 0.160 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2019 | 57 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 923 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 70 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 139 | 0.150 |
Why?
|
| Leptin | 1 | 2019 | 75 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 231 | 0.140 |
Why?
|
| Haplorhini | 1 | 2018 | 75 | 0.140 |
Why?
|
| Obesity | 3 | 2021 | 1244 | 0.140 |
Why?
|
| Anthracyclines | 1 | 2018 | 62 | 0.140 |
Why?
|
| Colistin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Soy Foods | 1 | 2017 | 8 | 0.130 |
Why?
|
| Genistein | 1 | 2017 | 17 | 0.130 |
Why?
|
| Phytoestrogens | 1 | 2017 | 26 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 47 | 0.130 |
Why?
|
| Ethinyl Estradiol | 1 | 2016 | 10 | 0.130 |
Why?
|
| Models, Theoretical | 2 | 2015 | 145 | 0.120 |
Why?
|
| Metabolomics | 1 | 2016 | 65 | 0.120 |
Why?
|
| Social Isolation | 1 | 2016 | 45 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2016 | 83 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2016 | 108 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 19 | 0.120 |
Why?
|
| Mitochondria | 1 | 2018 | 218 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2016 | 95 | 0.120 |
Why?
|
| Rats | 3 | 2017 | 1946 | 0.110 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 7 | 0.110 |
Why?
|
| Glutamine | 1 | 2014 | 10 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 29 | 0.110 |
Why?
|
| Thrombospondin 1 | 1 | 2014 | 7 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 80 | 0.100 |
Why?
|
| Aromatase Inhibitors | 1 | 2014 | 10 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2014 | 264 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 197 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 399 | 0.100 |
Why?
|
| Premenopause | 1 | 2014 | 55 | 0.100 |
Why?
|
| Ovary | 1 | 2014 | 69 | 0.100 |
Why?
|
| Glucose | 1 | 2014 | 194 | 0.100 |
Why?
|
| Estrogens | 1 | 2014 | 210 | 0.100 |
Why?
|
| Cathepsin D | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cathepsin L | 1 | 2013 | 1 | 0.100 |
Why?
|
| Burns | 1 | 2014 | 103 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 190 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 489 | 0.100 |
Why?
|
| Macrophages | 1 | 2014 | 216 | 0.090 |
Why?
|
| Pyrroles | 1 | 2013 | 62 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2014 | 265 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 222 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2014 | 484 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 97 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3812 | 0.090 |
Why?
|
| Angiotensins | 1 | 2011 | 42 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 46 | 0.080 |
Why?
|
| Fibronectins | 1 | 2010 | 40 | 0.080 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 103 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 426 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 67 | 0.080 |
Why?
|
| Fibrosis | 1 | 2010 | 129 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 178 | 0.080 |
Why?
|
| Adult | 1 | 2021 | 10015 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2017 | 5 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 452 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2015 | 71 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 41 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 834 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2015 | 268 | 0.050 |
Why?
|
| Adipokines | 1 | 2019 | 17 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2019 | 26 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 44 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 9 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 38 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 148 | 0.030 |
Why?
|
| Thiazoles | 1 | 2018 | 36 | 0.030 |
Why?
|
| Pyridines | 1 | 2018 | 87 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 196 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 13 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 40 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 52 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 35 | 0.030 |
Why?
|
| Cattle | 1 | 2017 | 118 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2016 | 10 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2016 | 7 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 17 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 24 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2017 | 92 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 47 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 45 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 59 | 0.030 |
Why?
|
| Isoflavones | 1 | 2017 | 104 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 230 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 90 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 295 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2019 | 365 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 270 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 273 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 269 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 953 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2016 | 146 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 362 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 250 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1118 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 233 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2014 | 77 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 35 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 202 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 304 | 0.030 |
Why?
|
| Phagosomes | 1 | 2013 | 6 | 0.020 |
Why?
|
| Lysosomes | 1 | 2013 | 11 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 214 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 1069 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 35 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 239 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 71 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 123 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 593 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 4136 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4267 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3618 | 0.010 |
Why?
|